Halozyme Therapeutics (HALO) Non-Current Debt (2021 - 2026)

Halozyme Therapeutics (HALO) has 6 years of Non-Current Debt data on file, last reported at $1.9 billion in Q1 2026.

• Non-Current Debt for Q1 2026 came in at $1.9 billion, up 28.42% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.9 billion (up 28.42% YoY), and the FY2025 annual result was $2.1 billion, up 42.29% from the prior year.
• Non-Current Debt slipped to $1.9 billion in Q1 2026 per HALO's latest filing, from $2.1 billion in the prior quarter.
• Over five years, Non-Current Debt peaked at $2.1 billion in Q4 2025 and troughed at $800.1 million in Q3 2025.
• A 5-year average of $1.5 billion and a median of $1.5 billion in 2024 frame the typical range for Non-Current Debt.
• The sharpest annual moves came in 2022 and 2025: Non-Current Debt surged 89.62% in 2022, then tumbled 46.81% in 2025.
• A 5-year view of Non-Current Debt shows it stood at $1.5 billion in 2022, then increased by 0.43% to $1.5 billion in 2023, then grew by 0.44% to $1.5 billion in 2024, then jumped by 42.29% to $2.1 billion in 2025, then fell by 9.65% to $1.9 billion in 2026.
• Business Quant data shows HALO's Non-Current Debt at $1.9 billion in Q1 2026, $2.1 billion in Q4 2025, and $800.1 million in Q3 2025.